Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. reports developments as a clinical-stage biopharmaceutical company focused on therapies for fibro-inflammatory diseases. Company news centers on Thykamine™, including preclinical data in MASH and pulmonary fibrosis models, anti-inflammatory and anti-fibrotic research, intellectual-property filings, manufacturing controls and its radiodermatitis prevention program.
Recurring updates also cover Devonian's cosmeceutical activities, its Quebec extraction facility and Altius Healthcare Group LP, a commercialization subsidiary that sells licensed prescription pharmaceutical products in Canada. Corporate news includes financial results, board and management changes, shareholder meeting outcomes, stock-option grants and capital-structure actions such as its common-share consolidation.
Devonian Health Group (OTCQB: DVHGF) announced that, in connection with an underwritten public offering, it anticipates listing its common shares and warrants on the NYSE American, with trading expected as early as August 21, 2026 under symbols “DHGR” and “DHGR WS”, subject to market conditions and final NYSE American authorization. The company will remain listed on the TSX Venture Exchange and has reserved symbol “DHGR” there, intending to change its TSXV trading symbol from “GSD” to “DHGR” at a later date.
Devonian Health Group (TSXV:GSD, OTCQB:DVHGF) announced a proposed underwritten public offering of common shares (and/or pre-funded warrants) and warrants, together with an expected listing of its common shares and warrants on the NYSE American under the symbols DHGR and DHGRW, respectively. The listing remains subject to final authorization of the company's application and ongoing compliance with exchange rules, and the Offering is subject to market conditions and regulatory approval, with size and pricing yet to be determined.
According to Devonian, its shares are expected to continue trading on the OTCQB until pricing of the Offering, after which OTCQB trading will terminate once the NYSE American listing is effective. The company has also reserved the symbol DHGR on the TSX Venture Exchange and intends to change its current symbol from GSD to DHGR at a later date. ThinkEquity is acting as sole book-running manager, and a registration statement has been filed with the SEC but is not yet effective; no securities will be offered or sold to investors resident in Québec or elsewhere in Canada in connection with this Offering.
Devonian Health Group (OTCQB: DVHGF) received Health Canada authorization to initiate a seamless adaptive Phase II/III clinical trial of PUR 0110 (Thykamine™) cream in pediatric patients with mild-to-moderate atopic dermatitis, covering the full intended age range from 3 months to 17 years.
The 12-week, randomized, double-blind, placebo-controlled study will enroll approximately 306 patients, testing 0.05% and 0.1% Thykamine™ cream versus placebo. The primary endpoint is Week 12 treatment success based on vIGA-AD (Clear/Almost Clear with ≥2-grade improvement). An independent safety committee will oversee adverse events, age-cohort progression, and a Phase II futility analysis to determine seamless transition to Phase III.
According to Devonian, this pediatric program builds on a prior adult Phase II trial in atopic dermatitis where Thykamine™ showed statistically significant efficacy and an excellent safety profile, and is supported by a global patent portfolio for the Thykamine™ and SUPREX™ platforms.
Devonian Health Group (OTCQB: DVHGF, TSXV: GSD) reported Q3 2026 and nine‑month results. Q3 net loss was $1.9M or $0.70/share, versus $4.8M or $1.94/share a year earlier. Nine‑month net loss was $5.7M or $2.07/share, compared with $5.6M or $2.28/share.
Cash totaled $0.7M on April 30, 2026, down from $7M on July 31, 2025; the company remains debt‑free. Devonian raised $2M via two private placements plus $0.2M from warrant exercises and is prioritizing development of Thykamine in radiodermatitis, pediatric atopic dermatitis, and exploratory work in MASH and fibrotic diseases.
Devonian Health Group (OTCQB: DVHGF) reported the results of its annual general and special meeting held March 27, 2026.
Shareholders elected eight directors, appointed MNP LLP as auditor for the fiscal year ending July 31, 2026, and approved an amendment to increase the stock option pool to 20% of issued shares (post‑consolidation), subject to TSXV final approval.
Devonian Health Group (OTCQB: DVHGF) reported a Q2 2026 net loss of $2.2M ($0.81/share) and a six-month loss of $3.8M ($1.37/share). Cash fell to $1.3M at January 31, 2026 from $7.0M on July 31, 2025. The company effected a 60-for-1 reverse share split on January 22, 2026 and remains debt-free.
Devonian is refocusing on its Thykamine™ biopharmaceutical program, prioritizing a pivotal radiodermatitis prevention study, advancing preclinical MASH and fibrosis work, and evaluating strategic options for its Altius distribution business.
Devonian (OTCQB: DVHGF) reported Feb 19, 2026 preclinical human liver-on-a-chip results showing dose-dependent anti-fibrotic and anti-inflammatory activity for Thykamine™. In a 14-day PhysioMimix® MASH model, Thykamine reduced fibrosis biomarkers, Type I collagen deposition and lowered IL-6/IL-8, with strongest effects at 0.1–0.2 mg/mL.
LDH remained low (no drug-induced liver injury signal). Company plans additional preclinical studies to further characterize disease-modifying potential in MASH and other fibrotic diseases.
Devonian (OTCQB: DVHGF) announced that a proprietary Thykamine™ fingerprint has been filed in two patent applications and will be used in all future Thykamine filings. The fingerprint defines eight chemical components in precise ratios using HPLC‑MS, with NMR confirmation showing ≥98% batch‑to‑batch confidence.
Biological potency assays in a U‑937 human cell model demonstrated equivalent activity across batches, including consistent inhibition of inflammatory cytokines RANTES and MIP‑1β. The fingerprint, NMR, and potency assays are being integrated into Thykamine's CMC framework to support pharmaceutical development and regulatory preparedness.
Devonian (OTCQB: DVHGF) reported additional preclinical molecular data from its STAM mouse MASH study showing dose-dependent anti-MASH, anti-inflammatory and anti-fibrotic gene effects for Thykamine.
Oral dosing at 0.5, 5.0 and 50.0 mg/kg once daily for three weeks down‑regulated 29 fibrosis/inflammation genes, with several genes reduced by approximately 80–90% versus placebo and regional liver‑lobe differences observed.
Devonian Health (OTCQB: DVHGF) reported positive preclinical results for Thykamine in a bleomycin-induced pulmonary fibrosis mouse model on Feb 10, 2026. Thykamine, given orally at doses including 0.5 mg/kg, produced statistically significant reductions in lung wet weight, fibrosis (Ashcroft) and inflammation versus bleomycin controls.
Gene expression changes included downregulation of Fn1, Col1a1, Col3a1, Col6a1/3, Birc5, Ccl2, Cxcl2 and increased Mmp9 with reduced Mmp13, suggesting controlled matrix remodeling and antifibrotic activity. Pirfenidone at 220 mg/kg did not reach significance on physiological endpoints.